Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas
about
PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variablesA collection of breast cancer cell lines for the study of functionally distinct cancer subtypesE-cadherin distribution in interleukin 6-induced cell-cell separation of ductal breast carcinoma cellsp53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomasCoexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breastVimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomasCathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years.Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomasp53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptorThe biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs.Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas.Expression of glutathione S-transferase B1, B2, Mu and Pi in breast cancers and their relationship to oestrogen receptor status.Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer.Vimentin expression in benign and malignant breast epithelium.Clinical significance of vimentin expression and Her-2 status in patients with gastric carcinoma.Identification of a cis-acting DNA antisilencer element which modulates vimentin gene expression.Vimentin expression is not associated with poor prognosis in breast cancer.The role of tumor-associated antigens in the biology and immunotherapy of breast cancer.SUM-159PT cells: a novel estrogen independent human breast cancer model system.Expression of mutant p53 gene in squamous carcinoma arising in patients with recessive dystrophic epidermolysis bullosa.Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor.The development of epithelial phenotypes in the human fetal and infant breast.Coexpression of cytokeratin and vimentin intermediate filaments in benign and malignant sweat gland tumors.Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer.Analysis of oncogenes and tumor suppressor genes in human breast cancer.Mutant p53—the commonest genetic abnormality in human cancer?
P2860
Q24564546-69463FCA-312F-42F9-97AB-57501496C2B0Q24647928-3AEED8B3-5366-49E1-B29F-2012614EB720Q35228257-7E4E5479-C951-4B21-975D-D938460AC87CQ35586221-9A2E4BC6-D88C-427F-8D6D-3BF3F5DA863EQ35811376-8E81429D-A3B9-4AA2-9330-A0F0FAAC65CCQ35811970-69D13BC1-6639-445F-BC2E-832C280B9F6AQ35811982-FEE1D50C-92A7-4DF6-898C-9BF5EAEA9B4DQ35812156-27F6DA15-B05E-4607-977A-B12F1E74DE71Q35832132-5B8EB7EC-23E9-4C13-9AD8-797A10F50860Q35832474-F95229DE-5773-4635-A77E-DF9874407E2EQ35994464-EA77F62E-B99C-4767-9F6D-71DA6D420DE6Q36286854-A9691B3F-0F5A-4D12-9092-5A67A2A8A5C6Q36338003-FD7A8752-5730-4280-9165-75D6768B0873Q36369621-0E2D2E76-A86A-4B20-A762-4FB4C31C0912Q36467856-75A86353-BE8D-44A3-B5DC-363C929FFDDAQ36738957-A7086996-014D-44CB-AEAC-CED97621982FQ37234527-31A42B3C-918E-4EDC-96CA-472229C39B01Q37700533-CD5E65FA-ED75-4490-9E94-348D82431D5DQ38329022-F785A0B2-08D6-4D85-942D-47647138F980Q38477486-D258336A-5D3B-41C6-88D2-72244C334E39Q40800301-C718EA04-88CE-4247-90D0-5D9923E0C86AQ40893693-5E9C5040-3A0E-4627-AB10-7B2AA7FF3F3EQ41115740-1B2EE3E4-AE9B-4BB5-8269-D205F0240DC4Q41668126-17251207-7C46-4A93-9F43-3E81525392E5Q42455730-80873253-1FA8-4E51-ABFF-A19AECABDE47Q42476241-D3443196-8704-491B-90DC-B87746FAC33CQ42500639-B597E190-93DC-44CB-8EF3-8CC99B7F159BQ42520778-058B0BE7-64A7-4830-B2BA-331CB6E0C6D4Q44750877-D88E45FE-9D0A-46F2-96C4-ED9304F0C6F7Q55387322-CDC5C595-BE35-4298-A1D8-69FF54C2B0FEQ58212569-4C33AE3A-2947-47CA-B99A-BA989128CCE2
P2860
Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Vimentin and p53 expression on ...... tor-negative breast carcinomas
@ast
Vimentin and p53 expression on ...... tor-negative breast carcinomas
@en
type
label
Vimentin and p53 expression on ...... tor-negative breast carcinomas
@ast
Vimentin and p53 expression on ...... tor-negative breast carcinomas
@en
prefLabel
Vimentin and p53 expression on ...... tor-negative breast carcinomas
@ast
Vimentin and p53 expression on ...... tor-negative breast carcinomas
@en
P2093
P2860
P356
P1476
Vimentin and p53 expression on ...... tor-negative breast carcinomas
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1988.81
P407
P577
1988-04-01T00:00:00Z